The National Institute on Deafness and Other Communication Disorders awarded Vulintus $1.5M for a two-year Phase II SBIR project to run a multi-site efficacy study of the OptiSpeech system for speech therapy and to create commercial-ready beta systems. Holle Carey is the principal investigator.